ClinicalTrials.gg
CompletedNCT02371629Updated Aug 9, 2019Results posted

A Study of the Efficacy and Safety of NVA237 in Patients With Moderate to Severe COPD

A Phase 4 interventional study of NVA237 and Placebo in Chronic Obstructive Pulmonary Disease, sponsored by Novartis Pharmaceuticals. Completed at 81 sites in 10 countries. Open to participants aged 41 Years to 84 Years. Per ClinicalTrials.gov, last updated 2019-08-09.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
776
Allocation
Randomized
Ages
41 Years to 84 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive — 2 open to participants now, 2 under way, 1 of them phase 3. Glycopyrrolate · Pulmonary Disease, Chronic Obstructive.

Enrollment
15th of 73
776 · median 152
Started
2015
with 7 others
Phase 4
11 of 73
1 open now
Registered
47th of 73
by date
Lead sponsor
19 of 73
Novartis Pharmaceuticals

Among the 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive, this one is the 15th largest by enrollment, is one of 8 that started in 2015, is one of 11 in phase 4, and was the 47th registered.

Pulmonary Disease, Chronic Obstructive

5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 856 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

2 of the 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About glycopyrrolate

Glycopyrrolate: first FDA approval 1961 (ROBINUL FORTE), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 558 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.

This study: 41 Years to 84 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive, or all of them as a file.
02

Study summary

This study is a post-authorization commitment to the European Medicines Agency (EMA). The study serves to determine whether the treatment of patients with stable, symptomatic Chronic Obstructive Pulmonary Disease (COPD) with the investigational drug NVA237 is efficient and safe. The efficacy and safety of the drug was tested for twice daily dosing against once daily dosing.

03

Conditions studied

  • Chronic Obstructive Pulmonary Disease

Keywords

  • Anticholinergic
  • Antimuscarinic
  • Chronic Obstructive Airway Disease
  • Chronic Obstructive Lung Disease
  • Chronic Obstructive Pulmonary Disease
  • COPD
  • LAMA
  • Lung Disease
  • Lung Diseases, Obstructive
  • Lung Function
  • Muscarinic receptor antagonist
  • Pulmonary Disease, Chronic Obstructive
  • Respiratory Tract Diseases
04

Who can participate

Ages eligible
41 Years to 84 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written must be obtained before any assessment is performed
  • Male and female adults aged ≥40 years
  • Patients with stable according to the current GOLD strategy (GOLD 2014)
  • Current or ex-smokers who have a smoking history of at least 10 pack years- an ex-smoker may be defined as a subject who has not smoked for ≥ 6 months at screening
  • mMRC grade of at least 2 at Visit 101
  • Patients with airflow limitation indicated by a post-bronchodilator ≥ 30 % and \< 80 % of the predicted normal, and a post-bronchodilator FEV1/FVC \< 0.70 at Visit 101.

Exclusion criteria

Exclusion Criteria:

  • Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test; Women of , defined as all women physiologically capable of becoming pregnant, unless they are using effective methods of during dosing of study treatment
  • Patients with Type I or uncontrolled Type II diabetes; Patients with a history of long syndrome or whose QTc measured at run-in (Fridericia method) is prolonged (>450 ms for males and >460 for females) and confirmed by a central assessor
  • Patients requiring long term oxygen therapy prescribed for >12 h per day; Patients with any history of asthma.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
776 participants (actual)

Study arms

  • Experimental
    NVA237 Twice daily

    Patients randomized to this arm received an NVA237 22 μg capsule in the morning and evening for 26 weeks. All participants received salbutamol as rescue medicine.

    Drug: NVA237 · Drug: Salbutamol

  • Experimental
    NVA237 Once daily

    Patients randomized to this arm received an NVA237 44 μg capsule in the morning and a placebo capsule in the evening for 26 weeks. All participants received salbutamol as rescue medicine.

    Drug: NVA237 · Drug: Placebo · Drug: Salbutamol

Interventions

  • DrugNVA237

    NVA237 capsules for inhalation, delivered via a Single Dose Dry Powder Inhaler (SDDPI) called Concept1

    Also known as: glycopyrronioum bromide

  • DrugPlacebo

    Placebo to NVA237

  • All patients received salbutamol (100 μg) as only rescue medication

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Trough Forced Expiratory Volume in 1 Second (FEV1) at Week 12

    Spirometry testing was performed in accordance with American Thoracic Society standards. Trough FEV1 defined as the mean of two measurements at 23 hours 15 minutes and 23 hour 45 minutes post dosing. Baseline FEV1 was defined as the average of the -45 minutes and -15 minutes FEV1 values taken on Day 1. An analysis-of-covariance (ANCOVA) for repeated measurements, also known as mixed model for repeated measures (MMRM), was performed for the change from baseline of trough FEV1 at Week 12. The model included treatment, COPD severity, baseline smoking status, baseline ICS use, region, and visit (Day 1, and Weeks 12 and 26) as factors and baseline FEV1 as a covariate.

    Time frame: Baseline, Week 12

Secondary outcomes

  1. Change From Baseline in Area Under The Curve (AUC) for Forced Expiratory Volume in One Second (FEV1) for Different Time Spans Post Dosing at Week 12

    The standardized Area Under the Curve (AUC) for Forced Expiratory Volume in one second (FEV1) is assessed for different time spans (0-12h, 0-24h, 12-24h) within the overall serial measurement post dosing at week 12 of treatment. Baseline FEV1 was defined as the average of the -45 minutes and -15 minutes FEV1 values taken on Day 1.

    Time frame: Baseline, 0-12 hour, 0-24 hour , 12-24 hour post dose at Week 12

  2. Change From Baseline in Area Under The Curve (AUC 0-12 Hour) for Forced Expiratory Volume in One Second (FEV1) Post Dosing at Day 1

    The standardized Area Under the Curve (AUC) for Forced Expiratory Volume in one second (FEV1) is assessed for 0-12 hour, post dosing at Day 1 of treatment. Baseline FEV1 was defined as the average of the -45 minutes and -15 minutes FEV1 values taken on Day 1.

    Time frame: Baseline, 0-12 hour post dose at Day 1

  3. Change From Baseline in Area Under The Curve (AUC) for Forced Expiratory Volume in One Second (FEV1) for Different Time Spans Post Dosing at Week 26

    The standardized Area Under the Curve (AUC) for Forced Expiratory Volume in one second (FEV1) is assessed for different time spans (0-12h, 0-24h, 12-24h) within the overall serial measurement post dosing at week 26 of treatment. Baseline FEV1 was defined as the average of the -45 minutes and -15 minutes FEV1 values taken on Day 1.

    Time frame: Baseline, 0-12 hour, 0-24 hour , 12-24 hour post dose at Week 26

  4. Change From Baseline in Total St. George's Respiratory Questionnaire (SGRQ) Score at Week 12 and Week 26

    The health status, as reported by the patients, is assessed using the St. George's Respiratory Questionnaire (SGRQ). The SGRQ contains 50 items divided into 2 parts covering 3 aspects of health related to COPD: * Part I covers "Symptoms" and is concerned with respiratory symptoms, their frequency and severity * Part II covers "Activity" and is concerned with activities that caused or are limited by breathlessness * Part II is also concerned with "Impacts", which covers a range of aspects concerned with social functioning and psychological disturbances resulting from airways disease. A score was calculated for each of these three subscales and the total score was calculated. In each case, the lowest possible value was 0 and the highest 100. Higher values corresponded to greater impairment of health status.

    Time frame: Baseline, 12 Weeks, 26 Weeks

  5. Percentage of Patients With a Clinically Significant Improvement in St George Respiratory Questionnaire at Week 12 and Week 26

    The health status, as reported by the patients, is assessed using the St. George's Respiratory Questionnaire (SGRQ). The SGRQ contains 50 items divided into 2 parts covering 3 aspects of health related to COPD: * Part I covers "Symptoms" and is concerned with respiratory symptoms, their frequency and severity * Part II covers "Activity" and is concerned with activities that caused or are limited by breathlessness * Part II is also concerned with "Impacts", which covers a range of aspects concerned with social functioning and psychological disturbances resulting from airways disease. A score was calculated for each of these three subscales and the total score was calculated. In each case, the lowest possible value was 0 and the highest 100. A clinically significant improvement is defined as ≥ 4 unit improvement from baseline score (a decrease of ≥ 4).

    Time frame: Baseline, 12 Weeks, 26 Weeks

  6. Change From Baseline in Transitional Dyspnea Index (TDI) Focal Score at Week 12 and Week 26

    Breathlessness at Week 12 and Week 26 is measured using the Transition Dyspnea Index (TDI). On day 1, breathlessness is assessed by the Baseline Dyspnea Index (BDI). Baseline Dyspnea Index (BDI)/Transition Dyspnea Index (TDI) focal score is based on three domains: functional impairment, magnitude of task and magnitude of effort and captures changes from baseline. BDI was measured at day 1 prior to the first dose with domain scores ranging from 0=very severe to 4=no impairment and a total score ranging from 0 to 12(best). TDI captures changes from baseline. Each domain is scored from -3=major deterioration to 3=major improvement to give an overall TDI focal score of -9 to 9. Higher numbers indicate a better score.

    Time frame: Baseline, 12 Weeks, 26 Weeks

  7. Percentage of Patients With a Clinically Important Improvement on Transitional Dyspnea Index (TDI) Focal Score at Week 12 and Week 26

    Breathlessness at Week 12 and Week 26 is measured using the Transition Dyspnea Index (TDI). On day 1, breathlessness is assessed by the Baseline Dyspnea Index (BDI). Baseline Dyspnea Index (BDI)/Transition Dyspnea Index (TDI) focal score is based on three domains: functional impairment, magnitude of task and magnitude of effort and captures changes from baseline. BDI was measured at day 1 prior to the first dose with domain scores ranging from 0=very severe to 4=no impairment and a total score ranging from 0 to 12(best). TDI captures changes from baseline. Each domain is scored from -3=major deterioration to 3=major improvement to give an overall TDI focal score of -9 to 9. Higher numbers indicate a better score. Clinically important improvement indicates ≥ 1 unit in the TDI focal score at Weeks 12 and 26 in comparison to BDI focal score (an increase of ≥ 1).

    Time frame: Baseline, 12 Weeks, 26 Weeks

  8. Change From Baseline in Trough Forced Expiratory Volume in 1 Second (FEV1) at Day 1 and Week 26

    Spirometry testing was performed in accordance with American Thoracic Society standards. Trough FEV1 defined as the mean of two measurements at 23 hours 15 minutes and 23 hour 45 minutes post dosing. Baseline FEV1 was defined as the average of the -45 minutes and -15 minutes FEV1 values taken on Day 1. An analysis-of-covariance (ANCOVA) for repeated measurements, also known as mixed model for repeated measures (MMRM), was performed for the change from baseline of trough FEV1. The model included treatment, COPD severity, baseline smoking status, baseline ICS use, region, and visit (Day 1, and Weeks 12 and 26) as factors and baseline FEV1 as a covariate.

    Time frame: Baseline, Day 1, Week 26

  9. Change From Baseline in Forced Vital Capacity (FVC) at Individual Timepoints at Week 26

    Mixed model for repeated measures was used to analyze change from baseline in FVC. Baseline FVC is defined as the average of the -45 min and -15 min FVC values taken on Day 1 prior to first dose.

    Time frame: Baseline, Week 26 (Day 183-184)

  10. Change From Baseline in Inspiratory Capacity (IC) at Individual Timepoints at Week 26

    Mixed model for repeated measures was used to analyze change from baseline in IC.

    Time frame: Baseline, Week 26 (Day 183-184)

  11. Change From Baseline in Forced Expiratory Volume in One Second (FEV1) at Individual Timepoints at Week 26

    Mixed model for repeated measures was used to analyze change from baseline in FEV1. Baseline FEV1 is defined as the average of the -45 min and -15 min FEV1 values taken on Day 1 prior to first dose.

    Time frame: Baseline, Week 26 (Day 183-184)

  12. Change From Baseline in the Percentage of Days With no Rescue Medication Use Over the 26 Weeks

    Patients report the number of puffs of rescue medication (salbutamol / albuterol) using an electronic diary. change from baseline in percentage of days without rescue medication usage over 26 weeks was analyzed.

    Time frame: Baseline, 26 Weeks

  13. Change From Baseline in Mean Daily COPD Symptom Score at Week 26

    Patients reported symptoms by using an electronic diary. The mean daily total symptom score, the mean morning symptom score and the mean evening symptom score were calculated for each patient over 26 weeks. Each symptom measured in a numeric rating scale of 0-10; 0 indicates no symptom and 10 indicates severe symptom. 0 is no waking due to symptoms, 1 woke up once, 2 woke up more than once due to symptoms ; 10 was the worst score.The daily score for an individual symptom score was the worst of the morning and evening scores on a particular day. If either the morning or evening score was missing for a symptom then the non-missing value was taken as the worst. A negative change indicates improvement. Only the scores for the 6 COPD symptoms (respiratory symptoms, cough, wheeze, production of sputum, sputum color, and breathlessness) were used to derive the total symptom score

    Time frame: Baseline, 26 Weeks

  14. Number of Patients With Adverse Events, Serious Adverse Events and Death

    This endpoint reports patients affected by any adverse events (AE), serious adverse events (SAE) and death. Only treatment emergent AE, SAE, deaths are reported for this endpoint.

    Time frame: 26 Weeks

07

Results

Posted Aug 9, 2019

Participant flow

Participant flow — Overall Study
MilestoneNVA237 Twice DailyNVA237 Once Daily
Started388388
Completed362363
Not completed2625
Withdrew: Patient decision1410
Withdrew: Adverse event88
Withdrew: Physician decision23
Withdrew: Death11
Withdrew: Noncompliance with study treatment10
Withdrew: Lack of efficacy02
Withdrew: Protocol deviation01

Outcome measures

PrimaryChange From Baseline in Trough Forced Expiratory Volume in 1 Second (FEV1) at Week 12

Spirometry testing was performed in accordance with American Thoracic Society standards. Trough FEV1 defined as the mean of two measurements at 23 hours 15 minutes and 23 hour 45 minutes post dosing. Baseline FEV1 was defined as the average of the -45 minutes and -15 minutes FEV1 values taken on Day 1. An analysis-of-covariance (ANCOVA) for repeated measurements, also known as mixed model for repeated measures (MMRM), was performed for the change from baseline of trough FEV1 at Week 12. The model included treatment, COPD severity, baseline smoking status, baseline ICS use, region, and visit (Day 1, and Weeks 12 and 26) as factors and baseline FEV1 as a covariate.

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · Liters
Change From Baseline in Trough Forced Expiratory Volume in 1 Second (FEV1) at Week 12
LitersNVA237 Twice DailyNVA237 Once Daily
Change From Baseline in Trough Forced Expiratory Volume in 1 Second (FEV1) at Week 120.092 ± 0.01260.059 ± 0.0125
Statistical analysis
  • NVA237 Twice Daily vs NVA237 Once Daily · Mixed model for repeated measure (MMRM) · p = 0.051 · Mean difference (net): 0.033 · 95% CI 0.000 to 0.066
SecondaryChange From Baseline in Area Under The Curve (AUC) for Forced Expiratory Volume in One Second (FEV1) for Different Time Spans Post Dosing at Week 12

The standardized Area Under the Curve (AUC) for Forced Expiratory Volume in one second (FEV1) is assessed for different time spans (0-12h, 0-24h, 12-24h) within the overall serial measurement post dosing at week 12 of treatment. Baseline FEV1 was defined as the average of the -45 minutes and -15 minutes FEV1 values taken on Day 1.

Time frame:
Baseline, 0-12 hour, 0-24 hour , 12-24 hour post dose at Week 12
Reported as:
Least squares mean · Liters
Change From Baseline in Area Under The Curve (AUC) for Forced Expiratory Volume in One Second (FEV1) for Different Time Spans Post Dosing at Week 12
LitersNVA237 Twice DailyNVA237 Once Daily
AUC (0-12 hour)0.136 ± 0.01190.106 ± 0.0118
AUC (0-24 hour)0.085 ± 0.01210.043 ± 0.0120
AUC (12-24 hour)0.035 ± 0.0125-0.019 ± 0.0124
SecondaryChange From Baseline in Area Under The Curve (AUC 0-12 Hour) for Forced Expiratory Volume in One Second (FEV1) Post Dosing at Day 1

The standardized Area Under the Curve (AUC) for Forced Expiratory Volume in one second (FEV1) is assessed for 0-12 hour, post dosing at Day 1 of treatment. Baseline FEV1 was defined as the average of the -45 minutes and -15 minutes FEV1 values taken on Day 1.

Time frame:
Baseline, 0-12 hour post dose at Day 1
Reported as:
Least squares mean · Liters
Change From Baseline in Area Under The Curve (AUC 0-12 Hour) for Forced Expiratory Volume in One Second (FEV1) Post Dosing at Day 1
LitersNVA237 Twice DailyNVA237 Once Daily
Change From Baseline in Area Under The Curve (AUC 0-12 Hour) for Forced Expiratory Volume in One Second (FEV1) Post Dosing at Day 10.143 ± 0.00890.139 ± 0.0087
SecondaryChange From Baseline in Area Under The Curve (AUC) for Forced Expiratory Volume in One Second (FEV1) for Different Time Spans Post Dosing at Week 26

The standardized Area Under the Curve (AUC) for Forced Expiratory Volume in one second (FEV1) is assessed for different time spans (0-12h, 0-24h, 12-24h) within the overall serial measurement post dosing at week 26 of treatment. Baseline FEV1 was defined as the average of the -45 minutes and -15 minutes FEV1 values taken on Day 1.

Time frame:
Baseline, 0-12 hour, 0-24 hour , 12-24 hour post dose at Week 26
Reported as:
Least squares mean · Liters
Change From Baseline in Area Under The Curve (AUC) for Forced Expiratory Volume in One Second (FEV1) for Different Time Spans Post Dosing at Week 26
LitersNVA237 Twice DailyNVA237 Once Daily
AUC (0-12 hour)0.123 ± 0.01210.091 ± 0.0120
AUC (0-24 hour)0.076 ± 0.01220.030 ± 0.0121
AUC (12-24 hour)0.032 ± 0.0127-0.028 ± 0.0126
SecondaryChange From Baseline in Total St. George's Respiratory Questionnaire (SGRQ) Score at Week 12 and Week 26

The health status, as reported by the patients, is assessed using the St. George's Respiratory Questionnaire (SGRQ). The SGRQ contains 50 items divided into 2 parts covering 3 aspects of health related to COPD: * Part I covers "Symptoms" and is concerned with respiratory symptoms, their frequency and severity * Part II covers "Activity" and is concerned with activities that caused or are limited by breathlessness * Part II is also concerned with "Impacts", which covers a range of aspects concerned with social functioning and psychological disturbances resulting from airways disease. A score was calculated for each of these three subscales and the total score was calculated. In each case, the lowest possible value was 0 and the highest 100. Higher values corresponded to greater impairment of health status.

Time frame:
Baseline, 12 Weeks, 26 Weeks
Reported as:
Least squares mean · score on a scale
Change From Baseline in Total St. George's Respiratory Questionnaire (SGRQ) Score at Week 12 and Week 26
score on a scaleNVA237 Twice DailyNVA237 Once Daily
Change from Baseline to WK 12-5.320 ± 0.6000-3.563 ± 0.5987
Change from Baseline to WK 26-6.587 ± 0.6543-4.644 ± 0.6527
SecondaryPercentage of Patients With a Clinically Significant Improvement in St George Respiratory Questionnaire at Week 12 and Week 26

The health status, as reported by the patients, is assessed using the St. George's Respiratory Questionnaire (SGRQ). The SGRQ contains 50 items divided into 2 parts covering 3 aspects of health related to COPD: * Part I covers "Symptoms" and is concerned with respiratory symptoms, their frequency and severity * Part II covers "Activity" and is concerned with activities that caused or are limited by breathlessness * Part II is also concerned with "Impacts", which covers a range of aspects concerned with social functioning and psychological disturbances resulting from airways disease. A score was calculated for each of these three subscales and the total score was calculated. In each case, the lowest possible value was 0 and the highest 100. A clinically significant improvement is defined as ≥ 4 unit improvement from baseline score (a decrease of ≥ 4).

Time frame:
Baseline, 12 Weeks, 26 Weeks
Reported as:
Number · percentage of patients
Percentage of Patients With a Clinically Significant Improvement in St George Respiratory Questionnaire at Week 12 and Week 26
percentage of patientsNVA237 Twice DailyNVA237 Once Daily
Change from Baseline to WK 1254.546.9
Change from Baseline to WK 2659.449.6
SecondaryChange From Baseline in Transitional Dyspnea Index (TDI) Focal Score at Week 12 and Week 26

Breathlessness at Week 12 and Week 26 is measured using the Transition Dyspnea Index (TDI). On day 1, breathlessness is assessed by the Baseline Dyspnea Index (BDI). Baseline Dyspnea Index (BDI)/Transition Dyspnea Index (TDI) focal score is based on three domains: functional impairment, magnitude of task and magnitude of effort and captures changes from baseline. BDI was measured at day 1 prior to the first dose with domain scores ranging from 0=very severe to 4=no impairment and a total score ranging from 0 to 12(best). TDI captures changes from baseline. Each domain is scored from -3=major deterioration to 3=major improvement to give an overall TDI focal score of -9 to 9. Higher numbers indicate a better score.

Time frame:
Baseline, 12 Weeks, 26 Weeks
Reported as:
Least squares mean · score on a scale
Change From Baseline in Transitional Dyspnea Index (TDI) Focal Score at Week 12 and Week 26
score on a scaleNVA237 Twice DailyNVA237 Once Daily
Change from Baseline to WK 121.346 ± 0.14300.849 ± 0.1433
Change from Baseline to WK 261.523 ± 0.15391.170 ± 0.1534
SecondaryPercentage of Patients With a Clinically Important Improvement on Transitional Dyspnea Index (TDI) Focal Score at Week 12 and Week 26

Breathlessness at Week 12 and Week 26 is measured using the Transition Dyspnea Index (TDI). On day 1, breathlessness is assessed by the Baseline Dyspnea Index (BDI). Baseline Dyspnea Index (BDI)/Transition Dyspnea Index (TDI) focal score is based on three domains: functional impairment, magnitude of task and magnitude of effort and captures changes from baseline. BDI was measured at day 1 prior to the first dose with domain scores ranging from 0=very severe to 4=no impairment and a total score ranging from 0 to 12(best). TDI captures changes from baseline. Each domain is scored from -3=major deterioration to 3=major improvement to give an overall TDI focal score of -9 to 9. Higher numbers indicate a better score. Clinically important improvement indicates ≥ 1 unit in the TDI focal score at Weeks 12 and 26 in comparison to BDI focal score (an increase of ≥ 1).

Time frame:
Baseline, 12 Weeks, 26 Weeks
Reported as:
Number · Percentage of patients
Percentage of Patients With a Clinically Important Improvement on Transitional Dyspnea Index (TDI) Focal Score at Week 12 and Week 26
Percentage of patientsNVA237 Twice DailyNVA237 Once Daily
Change from Baseline to WK 1256.952.0
Change from Baseline to WK 2661.154.6
SecondaryChange From Baseline in Trough Forced Expiratory Volume in 1 Second (FEV1) at Day 1 and Week 26

Spirometry testing was performed in accordance with American Thoracic Society standards. Trough FEV1 defined as the mean of two measurements at 23 hours 15 minutes and 23 hour 45 minutes post dosing. Baseline FEV1 was defined as the average of the -45 minutes and -15 minutes FEV1 values taken on Day 1. An analysis-of-covariance (ANCOVA) for repeated measurements, also known as mixed model for repeated measures (MMRM), was performed for the change from baseline of trough FEV1. The model included treatment, COPD severity, baseline smoking status, baseline ICS use, region, and visit (Day 1, and Weeks 12 and 26) as factors and baseline FEV1 as a covariate.

Time frame:
Baseline, Day 1, Week 26
Reported as:
Least squares mean · Liters
Change From Baseline in Trough Forced Expiratory Volume in 1 Second (FEV1) at Day 1 and Week 26
LitersNVA237 Twice DailyNVA237 Once Daily
Change from baseline to Day 10.119 ± 0.00990.070 ± 0.0097
Change from baseline to Week 260.104 ± 0.01290.056 ± 0.0128
SecondaryChange From Baseline in Forced Vital Capacity (FVC) at Individual Timepoints at Week 26

Mixed model for repeated measures was used to analyze change from baseline in FVC. Baseline FVC is defined as the average of the -45 min and -15 min FVC values taken on Day 1 prior to first dose.

Time frame:
Baseline, Week 26 (Day 183-184)
Reported as:
Least squares mean · Liters
Change From Baseline in Forced Vital Capacity (FVC) at Individual Timepoints at Week 26
LitersNVA237 Twice DailyNVA237 Once Daily
Day 183/-45 min:0.079 ± 0.01950.025 ± 0.0192
Day 183/-15 min:0.102 ± 0.01930.029 ± 0.0191
Day 183/5 min:0.159 ± 0.01940.085 ± 0.0194
Day 183/15 min:0.177 ± 0.01950.132 ± 0.0195
Day 183/30 min:0.194 ± 0.01920.144 ± 0.0191
Day 183/1 h:0.190 ± 0.01940.154 ± 0.0192
Day 183/2 h0.229 ± 0.01930.200 ± 0.0191
Day 183/3 h:0.229 ± 0.01970.186 ± 0.0192
Day 183/4 h:0.216 ± 0.01940.169 ± 0.0191
Day 183/6 h0.146 ± 0.01960.116 ± 0.0191
Day 183/8 h0.137 ± 0.01950.085 ± 0.0193
Day 183/10 h0.071 ± 0.01980.039 ± 0.0191
Day 183/12 h0.041 ± 0.02000.026 ± 0.0196
Day 183/13 h0.096 ± 0.01990.004 ± 0.0197
Day 184/16 h-0.014 ± 0.0207-0.081 ± 0.0206
Day 184/22 h-0.036 ± 0.0198-0.076 ± 0.0195
Day 184/23 h 15 min0.075 ± 0.02010.031 ± 0.0194
Day 184/23 h 45 min0.129 ± 0.01970.077 ± 0.0196
SecondaryChange From Baseline in Inspiratory Capacity (IC) at Individual Timepoints at Week 26

Mixed model for repeated measures was used to analyze change from baseline in IC.

Time frame:
Baseline, Week 26 (Day 183-184)
Reported as:
Least squares mean · Liters
Change From Baseline in Inspiratory Capacity (IC) at Individual Timepoints at Week 26
LitersNVA237 Twice DailyNVA237 Once Daily
Day 183/-20 min0.094 ± 0.02210.054 ± 0.0221
Day 183/25 min0.181 ± 0.02240.173 ± 0.0215
Day 183/1 h 55 min0.193 ± 0.02230.171 ± 0.0218
Day 183/3 h 55 min0.163 ± 0.02260.159 ± 0.0221
Day 183/7 h 55 min0.108 ± 0.02280.110 ± 0.0222
Day 183/11 h 55 min0.042 ± 0.02290.030 ± 0.0218
Day 184/23 h 40 min0.045 ± 0.02330.062 ± 0.0224
SecondaryChange From Baseline in Forced Expiratory Volume in One Second (FEV1) at Individual Timepoints at Week 26

Mixed model for repeated measures was used to analyze change from baseline in FEV1. Baseline FEV1 is defined as the average of the -45 min and -15 min FEV1 values taken on Day 1 prior to first dose.

Time frame:
Baseline, Week 26 (Day 183-184)
Reported as:
Least squares mean · Liters
Change From Baseline in Forced Expiratory Volume in One Second (FEV1) at Individual Timepoints at Week 26
LitersNVA237 Twice DailyNVA237 Once Daily
Day 183/-45 min0.058 ± 0.01200.012 ± 0.0119
Day 183/-15 min0.086 ± 0.01190.034 ± 0.0118
Day 183/5 min0.111 ± 0.01200.070 ± 0.0119
Day 183/15 min0.145 ± 0.01200.106 ± 0.0120
Day 183/30 min0.155 ± 0.01180.122 ± 0.0118
Day 183/1 h0.158 ± 0.01200.132 ± 0.0118
Day 183/2 h0.194 ± 0.01190.163 ± 0.0118
Day 183/3 h0.179 ± 0.01210.154 ± 0.0118
Day 183/4 h0.166 ± 0.01200.132 ± 0.0118
Day 183/6 h0.110 ± 0.01210.080 ± 0.0118
Day 183/8 h0.118 ± 0.01210.064 ± 0.0119
Day 183/10 h0.067 ± 0.01220.038 ± 0.0118
Day 183/12 h0.056 ± 0.01230.024 ± 0.0121
Day 183/13 h0.093 ± 0.01230.000 ± 0.0121
Day 184/16 h-0.001 ± 0.0128-0.063 ± 0.0127
Day 184/22 h-0.012 ± 0.0122-0.043 ± 0.0120
Day 184/23 h 15 min0.076 ± 0.01240.032 ± 0.0120
Day 184/23 h 45 min0.122 ± 0.01220.067 ± 0.0121
SecondaryChange From Baseline in the Percentage of Days With no Rescue Medication Use Over the 26 Weeks

Patients report the number of puffs of rescue medication (salbutamol / albuterol) using an electronic diary. change from baseline in percentage of days without rescue medication usage over 26 weeks was analyzed.

Time frame:
Baseline, 26 Weeks
Reported as:
Least squares mean · percentage of days
Change From Baseline in the Percentage of Days With no Rescue Medication Use Over the 26 Weeks
percentage of daysNVA237 Twice DailyNVA237 Once Daily
Change From Baseline in the Percentage of Days With no Rescue Medication Use Over the 26 Weeks16.574 ± 2.351915.363 ± 2.3927
SecondaryChange From Baseline in Mean Daily COPD Symptom Score at Week 26

Patients reported symptoms by using an electronic diary. The mean daily total symptom score, the mean morning symptom score and the mean evening symptom score were calculated for each patient over 26 weeks. Each symptom measured in a numeric rating scale of 0-10; 0 indicates no symptom and 10 indicates severe symptom. 0 is no waking due to symptoms, 1 woke up once, 2 woke up more than once due to symptoms ; 10 was the worst score.The daily score for an individual symptom score was the worst of the morning and evening scores on a particular day. If either the morning or evening score was missing for a symptom then the non-missing value was taken as the worst. A negative change indicates improvement. Only the scores for the 6 COPD symptoms (respiratory symptoms, cough, wheeze, production of sputum, sputum color, and breathlessness) were used to derive the total symptom score

Time frame:
Baseline, 26 Weeks
Reported as:
Least squares mean · score on a scale
Change From Baseline in Mean Daily COPD Symptom Score at Week 26
score on a scaleNVA237 Twice DailyNVA237 Once Daily
Change in mean daily-1.336 ± 0.1141-1.107 ± 0.1160
Change in mean morning-1.032 ± 0.1304-0.828 ± 0.1318
Change in mean evening-1.205 ± 0.1141-1.056 ± 0.1152
SecondaryNumber of Patients With Adverse Events, Serious Adverse Events and Death

This endpoint reports patients affected by any adverse events (AE), serious adverse events (SAE) and death. Only treatment emergent AE, SAE, deaths are reported for this endpoint.

Time frame:
26 Weeks
Reported as:
Number · Count of Participants
Number of Patients With Adverse Events, Serious Adverse Events and Death
Count of ParticipantsNVA237 Twice DailyNVA237 Once Daily
Patients with at least one AE203224
Patients with at least one SAE3330
Death11

Adverse events

Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
NVA237 22 mcg b.i.d.1/388 (0.3%)33/388 (8.5%)126/388 (32.5%)
NVA237 44 mcg o.d.2/388 (0.5%)30/388 (7.7%)152/388 (39.2%)
Most frequent serious events
Showing 10 of 38
Most frequent serious events
EventNVA237 22 mcg b.i.d.NVA237 44 mcg o.d.
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders11/38815/388
PneumoniaInfections and infestations3/3884/388
Atrial fibrillationCardiac disorders3/3882/388
Angina unstableCardiac disorders2/3880/388
Bronchial carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)2/3880/388
SchizophreniaPsychiatric disorders2/3880/388
Acute respiratory failureRespiratory, thoracic and mediastinal disorders2/3880/388
Atrial flutterCardiac disorders1/3880/388
Atrial tachycardiaCardiac disorders1/3880/388
Cardiac failure chronicCardiac disorders1/3880/388
Most frequent other events
Most frequent other events
EventNVA237 22 mcg b.i.d.NVA237 44 mcg o.d.
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders74/38899/388
NasopharyngitisInfections and infestations37/38854/388
HypertensionVascular disorders10/38814/388
BronchitisInfections and infestations10/3883/388
DyspnoeaRespiratory, thoracic and mediastinal disorders9/3882/388
HeadacheNervous system disorders4/3888/388

Baseline characteristics

Randomized set

Age, Continuous
Age, Continuous(years)NVA237 Twice DailyNVA237 Once DailyTotal
Mean63.2 ± 7.7163.6 ± 7.6663.4 ± 7.68
Sex: Female, Male
Sex: Female, Male(Participants)NVA237 Twice DailyNVA237 Once DailyTotal
Female122111233
Male266277543
08

Study locations

81 sites
  • Novartis Investigative Site
    Genk, Limburg 3600, Belgium
  • Novartis Investigative Site
    Jambes, Namur 5100, Belgium
  • Novartis Investigative Site
    Sevlievo, Gabrovo 5400, Bulgaria
  • Novartis Investigative Site
    Sofia, Sofia-Grad 1336, Bulgaria
  • Novartis Investigative Site
    Gabrovo, 5300, Bulgaria
  • Novartis Investigative Site
    Kozloduj, 3320, Bulgaria
  • Novartis Investigative Site
    Lom, 3600, Bulgaria
  • Novartis Investigative Site
    Lovech, 5500, Bulgaria
  • Novartis Investigative Site
    Montana, 3400, Bulgaria
  • Novartis Investigative Site
    Razgrad, 7200, Bulgaria
  • Novartis Investigative Site
    Roman, 3130, Bulgaria
  • Novartis Investigative Site
    Ruse, 7000, Bulgaria
  • Novartis Investigative Site
    Silistra, 7500, Bulgaria
  • Novartis Investigative Site
    Sliven, 8800, Bulgaria
  • Novartis Investigative Site
    Smolyan, 4700, Bulgaria
  • Novartis Investigative Site
    Sofia, 1202, Bulgaria
  • Novartis Investigative Site
    Sofia, 1233, Bulgaria
  • Novartis Investigative Site
    Sofia, 1431, Bulgaria
  • Novartis Investigative Site
    Troyan, 5600, Bulgaria
  • Novartis Investigative Site
    Veliko Tarnovo, 5000, Bulgaria
  • Novartis Investigative Site
    Vidin, 3700, Bulgaria
  • Novartis Investigative Site
    Turku, FIN-20100, Finland
  • Novartis Investigative Site
    Heidelberg, Baden-Württemberg 69126, Germany
  • Novartis Investigative Site
    Hannover, Niedersachsen 30159, Germany
  • Novartis Investigative Site
    Hannover, Niedersachsen 30167, Germany
  • Novartis Investigative Site
    Koblenz, Rheinland-Pfalz 56068, Germany
  • Novartis Investigative Site
    Großhansdorf, Schleswig-Holstein 22927, Germany
  • Novartis Investigative Site
    Berlin, 10117, Germany
  • Novartis Investigative Site
    Dresden, 01069, Germany
  • Novartis Investigative Site
    Frankfurt, 60596, Germany
  • Novartis Investigative Site
    Greifswald, 17475, Germany
  • Novartis Investigative Site
    Lubeck, 23552, Germany
  • Novartis Investigative Site
    Schwerin, 19055, Germany
  • Novartis Investigative Site
    Wiesbaden, 65187, Germany
  • Novartis Investigative Site
    Balassagyarmat, 2660, Hungary
  • Novartis Investigative Site
    Debrecen, 4032, Hungary
  • Novartis Investigative Site
    Farkasgyepu, 8582, Hungary
  • Novartis Investigative Site
    Pecs, 7635, Hungary
  • Novartis Investigative Site
    Sopron, H-9400, Hungary
  • Novartis Investigative Site
    Szarvas, 5540, Hungary
  • Novartis Investigative Site
    Szeged, 6722, Hungary
  • Novartis Investigative Site
    Rehovot, 7610001, Israel
  • Novartis Investigative Site
    Wroclaw, Dolnoslaskie 53-301, Poland
  • Novartis Investigative Site
    Lodz, Lódzkie 90-153, Poland
  • Novartis Investigative Site
    Tarnow, Malopolskie 33-100, Poland
  • Novartis Investigative Site
    Chorzow, Slaskie 41-500, Poland
  • Novartis Investigative Site
    Bialystok, 15-044, Poland
  • Novartis Investigative Site
    Gdansk, 80 952, Poland
  • Novartis Investigative Site
    Kielce, 25-751, Poland
  • Novartis Investigative Site
    Lodz, 90-141, Poland
  • Novartis Investigative Site
    Sopot, 81-741, Poland
  • Novartis Investigative Site
    Wilkowice, 43-365, Poland
  • Novartis Investigative Site
    Craiova, Dolj 200515, Romania
  • Novartis Investigative Site
    Constanta, Jud. Constanta 900002, Romania
  • Novartis Investigative Site
    Tg Mures, Mures 540136, Romania
  • Novartis Investigative Site
    Timisoara, Timis 300310, Romania
  • Novartis Investigative Site
    Baia Mare, Romania
  • Novartis Investigative Site
    Bucharest, 030317, Romania
  • Novartis Investigative Site
    Bucuresti, 050159, Romania
  • Novartis Investigative Site
    Cluj Napoca, 400162, Romania
  • Novartis Investigative Site
    Cluj-Napoca, 400371, Romania
  • Novartis Investigative Site
    Kazan, Tatarstan Republic 420015, Russian Federation
  • Novartis Investigative Site
    Chelyabinsk, 454021, Russian Federation
  • Novartis Investigative Site
    Izhevsk, 426061, Russian Federation
  • Novartis Investigative Site
    Kemerovo, 650002, Russian Federation
  • Novartis Investigative Site
    Kemerovo, 650099, Russian Federation
  • Novartis Investigative Site
    N.Novgorod, 603126, Russian Federation
  • Novartis Investigative Site
    Nizhny Novgorod, 603011, Russian Federation
  • Novartis Investigative Site
    Ryazan, 390039, Russian Federation
  • Novartis Investigative Site
    Sestroretsk, 197706, Russian Federation
  • Novartis Investigative Site
    Smolensk, 214019, Russian Federation
  • Novartis Investigative Site
    St Petersburg, 194325, Russian Federation
  • Novartis Investigative Site
    St. Petersburg, 197022, Russian Federation
  • Novartis Investigative Site
    Yaroslavl, 150000, Russian Federation
  • Novartis Investigative Site
    Yaroslavl, 150003, Russian Federation
  • Novartis Investigative Site
    Yaroslavl, 150062, Russian Federation
  • Novartis Investigative Site
    Linkoping, Ostergotlands Lan 587 58, Sweden
  • Novartis Investigative Site
    Malmo, Skane Lan 21152, Sweden
  • Novartis Investigative Site
    Lidingo, Sodermanlands Lan 18158, Sweden
  • Novartis Investigative Site
    Göteborg, Vastra Gotalands Lan SE-413 45, Sweden
  • Novartis Investigative Site
    Lund, SE-221 85, Sweden
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2015 to primary completion in Nov 2016, 16 months.

Results were first posted in Aug 2019, 2 years 8 months after primary completion.

Of 71 industry-sponsored phase 4 interventional studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 22. This study's 16 months is close to that.

Counting every sponsor, half of 157 studies reached it within 19 months; a quarter within 12 and three quarters within 40.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 19, 2015
First posted
Feb 25, 2015
StartActual
Jun 24, 2015
Primary completionActual
Nov 16, 2016
CompletionActual
Nov 16, 2016
Results first posted
Aug 9, 2019
Last update
Aug 9, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 9, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02371629
Responsible party
Sponsor
First posted
Feb 25, 2015
Start date
Jun 24, 2015
Primary completion
Nov 16, 2016
Completion
Nov 16, 2016
Results posted
Aug 9, 2019
Last update
Aug 9, 2019

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Glycopyrrolate

Start the discussion